Crinetics Pharmaceuticals (CRNX) Net Cash Flow (2017 - 2026)

Crinetics Pharmaceuticals' Net Cash Flow history runs 10 years deep, the most recent figure standing at $12.8 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 107.54% year-over-year to $12.8 million in Q1 2026; TTM through Mar 2026 was $19.4 million, a 106.43% increase from a year earlier, with the FY2025 full-year figure at -$163.4 million, down 177.94% from the prior year.
• Net Cash Flow climbed to $12.8 million in Q1 2026 per CRNX's latest filing, from -$9.8 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $341.0 million in Q1 2024 and bottomed at -$170.0 million in Q1 2025.
• The 5-year median for Net Cash Flow is -$9.8 million (2025), against an average of -$5.1 million.
• Biggest YoY gain for Net Cash Flow was 3902.19% in 2024; the steepest drop was 5613.71% in 2024.
• Year by year, Net Cash Flow stood at $1.8 million in 2022, then plunged by 5091.37% to -$87.9 million in 2023, then jumped by 40.02% to -$52.7 million in 2024, then surged by 81.49% to -$9.8 million in 2025, then surged by 231.29% to $12.8 million in 2026.
• Per Business Quant, the three latest CRNX Net Cash Flow figures stand at $12.8 million (Q1 2026), -$9.8 million (Q4 2025), and $57.2 million (Q3 2025).